Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares tick higher; Aegon shines on forecast raise

Thu, 11th Aug 2022 17:29

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

The pan-European STOXX 600 index rose 0.1%, after clocking its best session in nearly two weeks on Wednesday on bets that a softer-than-expected U.S. inflation reading would encourage the Federal Reserve to become less aggressive on interest rates hikes.

"Even if European stocks are not rallying as some of their counterparts today, they're going up as the interpretation by markets is that the inflation numbers were synonymous with the Fed changing its policy," said Sebastian Paris-Horvitz, head of research at La Banque Postale Asset Management.

Money markets are pricing in over a 60% chance of a 50 bps hike from the Fed at next month's meeting.

Oil stocks led gains as crude prices rose by over 1% after the International Energy Agency raised its oil demand growth forecast for the year.

Healthcare shares led losses, dragged by declines in GSK, Sanofi and Haleon amid growing concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Miners also fell 0.8% on weak results from Antofagasta. The company's shares declined 2.2% and dragged peer Rio Tinto down 3.7%.

The STOXX 600 is down about 10% so far this year, compared with a more than 11% decline for Wall Street's S&P 500 index . U.S. equities are heavily dependent on moves in big technology stocks, which fell sharply in the first half of the year on worries over rising interest rates.

"The big decline in global markets in the first quarter was associated with big growth stocks in the U.S. falling, and therefore Europe, which is less heavy on those, outperformed," Paris-Horvitz added.

Still, Europe is struggling with the fallout of the war in Ukraine as it looks to source energy from non-Russian sources.

Germany, often referred to as the European Union's economic engine, is also struggling with scant rainfall. Low water levels on the Rhine, Germany's commercial artery, have disrupted shipping and pushed freight costs up more than five-fold.

Among stocks, Aegon jumped 8.9% after raising forecasts for full-year operating capital generation and 2021-2023 free cash flow. Zurich Insurance Group added 1.7% as it reported a better-than-expected profit gain in the first half.

Siemens gained 0.7%. The engineering group said it continued to see strong industrial demand during its third quarter, but a writedown at Siemens Energy resulted in its first quarterly loss in nearly 12 years.

(Reporting by Shreyashi Sanyal, Anisha Sircar and Johann M Cherian in Bengaluru; Editing by Sriraj Kalluvila and Mike Harrison)

More News
10 Nov 2022 16:34

Sanofi, GSK score late win with EU COVID booster approval

Nov 10 (Reuters) - Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.

Read more
4 Nov 2022 07:00

Sanofi, Astra win EU approval for prevention of infant RSV

Nov 4 (Reuters) - The European Commission on Friday approved Sanofi and AstraZeneca's Beyfortus for the prevention of a common and highly contagious type of respiratory infections in infants.

Read more
2 Nov 2022 15:47

New GSK maintains strong start, but Zantac litigation looms large

Q3 profit, sales beat expectations

*

Read more
29 Sep 2022 11:44

Oddo BHF flags European pharma's attractive growth profile, prefers Novo Nordisk, AstraZeneca

Read more
26 Sep 2022 15:22

GSK selects Burberry's Brown as its first female CFO

Brown to join GSK in April

*

Read more
20 Sep 2022 08:58

Haleon believes it is not liable for any potential Zantac liabilities

LONDON, Sept 20 (Reuters) - Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.

Read more
20 Sep 2022 07:14

Haleon rejects Zantac indemnification requests from GSK, Pfizer

LONDON, Sept 20 (Reuters) - Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Read more
5 Sep 2022 15:24

Sanofi sees EU regulatory decision on its COVID booster in weeks

BRUSSELS, Sept 5 (Reuters) - The European Union's drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.

Read more
30 Aug 2022 17:14

European stocks fall for third day as rate hike, recession fears grow

Aug 30 (Reuters) - European shares ended lower on Tuesday, failing to shrug off fears of higher interest rates amid a burgeoning energy crisis and looming recession.

Read more
17 Aug 2022 18:10

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Read more
17 Aug 2022 17:22

European shares slip on inflation worries, Germany leads fall

Aug 17 (Reuters) - European shares slid on Wednesday and bond yields rallied after a sharp rise in UK inflation brought the spotlight back to more monetary tightening amid data which showed euro zone economic growth was slightly less robust in the second quarter.

Read more
17 Aug 2022 15:15

Plaintiff in first Zantac lawsuit set for trial drops case

Aug 17 (Reuters) - The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.

Read more
17 Aug 2022 08:21

GSK shares ease after plaintiff in first Zantac lawsuit drops case

LONDON, Aug 17 (Reuters) - Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case.

Read more
15 Aug 2022 22:17

UK first to approve Omicron COVID shot with Moderna nod

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

Read more
12 Aug 2022 17:17

European shares rise as healthcare, leisure stocks gain

Aug 12 (Reuters) - European shares rose on Friday after drugmakers rebounded following a slump in the previous session, and Flutter fanned a rally in the travel and leisure sector after an upbeat earnings forecast.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.